PULIKE(603566.SH)

Last Updated 00:00:00
longbridge loading
Company Encyclopedia
View More
name
PULIKE
603566.SH
Pulike Biological Engineering, Inc. engages in the research, development, production, and sale of veterinary biological products, chemical drugs, and traditional Chinese veterinary drugs. The company offers vaccines, antibodies, and medicines for swine and poultry, as well as disinfectants. Pulike Biological Engineering, Inc.
2.788 T
603566.SHMarket value -Rank by Market Cap -/-

Financial Score

20/05/2026 Update
C
PharmaceuticalsIndustry
Industry Ranking151/215
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE6.49%C
    • Profit Margin16.30%A
    • Gross Margin54.89%B
  • Growth ScoreC
    • Revenue YoY-2.32%D
    • Net Profit YoY45.95%B
    • Total Assets YoY3.97%C
    • Net Assets YoY3.49%C
  • Cash ScoreC
    • Cash Flow Margin157.92%B
    • OCF YoY-2.32%D
  • Operating ScoreD
    • Turnover0.34D
  • Debt ScoreA
    • Gearing Ratio13.82%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Huachuang Securities: In the first three quarters, most vaccine varieties saw year-on-year growth in batch approvals, and pet vaccines continued to maintain a high growth rate

    Zhitong·
    SH
    603392
    -2.45%
    SH
    600201
    -2.12%
    SH
    603566
    -0.26%
    Zhitong·
    SH
    603392
    -2.45%
    SH
    600201
    -2.12%
    SH
    603566
    -0.26%

    Huachuang Securities: In August, the growth of vaccines for diarrhea, brucellosis, and feline trivalent was strong, and the raw materials for veterinary drugs are entering a peak season with price increases

    Zhitong·
    SZ
    300119
    -1.05%
    SH
    600201
    -2.12%
    SZ
    300142
    -1.20%
    Zhitong·
    SZ
    300119
    -1.05%
    SH
    600201
    -2.12%
    SZ
    300142
    -1.20%

    PULIKE: 265 million idle fundraising cash management matures, recovering principal of 821 million with earnings of 3.6653 million

    Zhitong·
    SH
    603566
    -0.26%
    Zhitong·
    SH
    603566
    -0.26%

    Guohai Securities: The "Matthew Effect" in the animal protection industry intensifies, and pet pharmaceuticals and overseas expansion are expected to open up medium to long-term growth space

    Zhitong·
    SZ
    300119
    -1.05%
    SH
    688098
    -1.88%
    SZ
    002688
    -1.85%
    Zhitong·
    SZ
    300119
    -1.05%
    SH
    688098
    -1.88%
    SZ
    002688
    -1.85%

    PULIKE issued a profit forecast, expecting a year-on-year increase of 44.70% to 64.98% in net profit attributable to the parent company in the first half of the year

    Zhitong·
    SH
    603566
    -0.26%
    Zhitong·
    SH
    603566
    -0.26%
    © 2026 Longbridge｜Disclaimer